PD-1/OX40 targeting bispecific antibody (Immune Pharmaceuticals)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePD-1/OX40 targeting bispecific antibody (Immune Pharmaceuticals)

Drug Alias Namedual PD-1 checkpoint inhibitor/OX40 costimulator (Immune Pharmaceuticals)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed cell death protein 1 blockersTumor necrosis factor receptor superfamily member 4 agonists

TargetsTumor necrosis factor receptor superfamily member 4Programmed cell death protein 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIsrael

CombinationsNo

Global Highest StatusSuspended

Highest Status in ChinaN/A

Originator CompaniesImmune Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmune Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A